An interventional study of Acute oral CBD supplementation and Acute oral placebo supplementation in Glucose Metabolism Disorders (Including Diabetes Mellitus), Lipid Metabolism Disorders and Appetitive Behavior, sponsored by Loughborough University. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Loughborough University · Not applicable, Interventional, and Prevention
CBD may affect metabolic control and energy intake. However, there is currently little data regarding these specific outcomes in humans. Therefore, this study will investigate whether a single 300 mg dose of CBD can improve metabolic control following a meal and/or reduce energy intake at a subsequent meal. Healthy, adult volunteers will complete two conditions in a crossover design, comparing outcomes following both CBD and placebo supplementation.
264 studies on the registry are indexed under Glucose Metabolism Disorders; 37 are open to participants now.
This study's enrollment of 15 is below the median of 50 across 214 interventional studies indexed under Glucose Metabolism Disorders.
Browse Glucose Metabolism Disorders studies →Loughborough University is the lead sponsor of 75 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
300 mg CBD (KannaSwiss, Kölliken, Switzerland) dissolved in 1 ml hemp oil. Provided orally in gelatin capsules.
Dietary Supplement: Acute oral CBD supplementation
1 ml hemp oil. Provided orally in gelatin capsules.
Dietary Supplement: Acute oral placebo supplementation
1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
Energy intake
Self-selected energy intake at an ad libitum mixed meal
Time frame: ~5-30 minutes (time taken to eat a single meal)
Postprandial Glycaemia
Plasma glucose response to a mixed meal (plasma glucose concentrations and area under curve)
Time frame: 3 hours
Postprandial Triglyceridaemia
Plasma triglyceride response to a mixed meal (plasma triglyceride concentrations and area under curve)
Time frame: 3 hours
Postprandial Insulinaemia
Plasma Insulin response to a mixed meal (plasma insulin concentrations and area under curve)
Time frame: 3 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Apr 2022, 7 months.
Of 100 non-industry interventional studies with no phase under Glucose Metabolism Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 41. This study's 7 months is below that.
Counting every sponsor, half of 110 studies reached it within 19 months; a quarter within 8 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glucose Metabolism Disorders →
Loughborough University